Antibody response to human papillomavirus vaccine in subjects with inherited bone marrow failure syndromes

Blanche P. Alter, Neelam Giri, Yuanji Pan, Sharon A. Savage, Ligia A. Pinto

Research output: Contribution to journalArticle

Abstract

Patients with Fanconi anemia (FA) and other inherited bone marrow failure syndromes (IBMFS) have extremely high risks of squamous cell head and neck, and gynecologic carcinomas. In the general population, these sites are often associated with infection with human papillomaviruses (HPV), particularly HPV16 and HPV18. Our objectives were to measure the levels of HPV antibodies in unvaccinated patients, and to determine whether these patients developed and maintained similar levels of antibodies as those observed in healthy women, following vaccination with the currently licensed HPV L1 virus-like particles (VLP) vaccines. We measured anti-HPV IgG antibody levels in sera from patients using an HPV16 or HPV18 L1 VLP enzyme-linked immunoabsorbent assay. Most unvaccinated patients did not have detectable antibody levels, except for a few women above age 25. Both FA and other IBMFS patients developed antibody levels following vaccination that were similar to those previously described in healthy women, and those levels appeared to be sustained out to 5 years after immunization. Thus, antibody responses to the HPV L1 VLP vaccine in patients with FA and other IBMFS appeared to be similar to the responses reported in the general population, implying potential efficacy against future infections with the HPV types contained in the vaccine.

Original languageEnglish (US)
Pages (from-to)1169-1173
Number of pages5
JournalVaccine
Volume32
Issue number10
DOIs
StatePublished - Feb 26 2014
Externally publishedYes

Fingerprint

Papillomavirus Vaccines
Papillomaviridae
bone marrow
Antibody Formation
vaccines
antibodies
Fanconi Anemia
Virus-Like Particle Vaccines
virus-like particle vaccines
Antibodies
Vaccination
vaccination
virus-like particles
Infection
Bone Marrow failure syndromes
infection
Virion
Population
neck
carcinoma

Keywords

  • Dyskeratosis congenita
  • Fanconi anemia
  • Human papillomavirus
  • Inherited bone marrow failure syndromes
  • Vaccine

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Antibody response to human papillomavirus vaccine in subjects with inherited bone marrow failure syndromes. / Alter, Blanche P.; Giri, Neelam; Pan, Yuanji; Savage, Sharon A.; Pinto, Ligia A.

In: Vaccine, Vol. 32, No. 10, 26.02.2014, p. 1169-1173.

Research output: Contribution to journalArticle

Alter, Blanche P. ; Giri, Neelam ; Pan, Yuanji ; Savage, Sharon A. ; Pinto, Ligia A. / Antibody response to human papillomavirus vaccine in subjects with inherited bone marrow failure syndromes. In: Vaccine. 2014 ; Vol. 32, No. 10. pp. 1169-1173.
@article{944df741d64c47fd85922e1204cf425a,
title = "Antibody response to human papillomavirus vaccine in subjects with inherited bone marrow failure syndromes",
abstract = "Patients with Fanconi anemia (FA) and other inherited bone marrow failure syndromes (IBMFS) have extremely high risks of squamous cell head and neck, and gynecologic carcinomas. In the general population, these sites are often associated with infection with human papillomaviruses (HPV), particularly HPV16 and HPV18. Our objectives were to measure the levels of HPV antibodies in unvaccinated patients, and to determine whether these patients developed and maintained similar levels of antibodies as those observed in healthy women, following vaccination with the currently licensed HPV L1 virus-like particles (VLP) vaccines. We measured anti-HPV IgG antibody levels in sera from patients using an HPV16 or HPV18 L1 VLP enzyme-linked immunoabsorbent assay. Most unvaccinated patients did not have detectable antibody levels, except for a few women above age 25. Both FA and other IBMFS patients developed antibody levels following vaccination that were similar to those previously described in healthy women, and those levels appeared to be sustained out to 5 years after immunization. Thus, antibody responses to the HPV L1 VLP vaccine in patients with FA and other IBMFS appeared to be similar to the responses reported in the general population, implying potential efficacy against future infections with the HPV types contained in the vaccine.",
keywords = "Dyskeratosis congenita, Fanconi anemia, Human papillomavirus, Inherited bone marrow failure syndromes, Vaccine",
author = "Alter, {Blanche P.} and Neelam Giri and Yuanji Pan and Savage, {Sharon A.} and Pinto, {Ligia A.}",
year = "2014",
month = "2",
day = "26",
doi = "10.1016/j.vaccine.2013.11.048",
language = "English (US)",
volume = "32",
pages = "1169--1173",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "10",

}

TY - JOUR

T1 - Antibody response to human papillomavirus vaccine in subjects with inherited bone marrow failure syndromes

AU - Alter, Blanche P.

AU - Giri, Neelam

AU - Pan, Yuanji

AU - Savage, Sharon A.

AU - Pinto, Ligia A.

PY - 2014/2/26

Y1 - 2014/2/26

N2 - Patients with Fanconi anemia (FA) and other inherited bone marrow failure syndromes (IBMFS) have extremely high risks of squamous cell head and neck, and gynecologic carcinomas. In the general population, these sites are often associated with infection with human papillomaviruses (HPV), particularly HPV16 and HPV18. Our objectives were to measure the levels of HPV antibodies in unvaccinated patients, and to determine whether these patients developed and maintained similar levels of antibodies as those observed in healthy women, following vaccination with the currently licensed HPV L1 virus-like particles (VLP) vaccines. We measured anti-HPV IgG antibody levels in sera from patients using an HPV16 or HPV18 L1 VLP enzyme-linked immunoabsorbent assay. Most unvaccinated patients did not have detectable antibody levels, except for a few women above age 25. Both FA and other IBMFS patients developed antibody levels following vaccination that were similar to those previously described in healthy women, and those levels appeared to be sustained out to 5 years after immunization. Thus, antibody responses to the HPV L1 VLP vaccine in patients with FA and other IBMFS appeared to be similar to the responses reported in the general population, implying potential efficacy against future infections with the HPV types contained in the vaccine.

AB - Patients with Fanconi anemia (FA) and other inherited bone marrow failure syndromes (IBMFS) have extremely high risks of squamous cell head and neck, and gynecologic carcinomas. In the general population, these sites are often associated with infection with human papillomaviruses (HPV), particularly HPV16 and HPV18. Our objectives were to measure the levels of HPV antibodies in unvaccinated patients, and to determine whether these patients developed and maintained similar levels of antibodies as those observed in healthy women, following vaccination with the currently licensed HPV L1 virus-like particles (VLP) vaccines. We measured anti-HPV IgG antibody levels in sera from patients using an HPV16 or HPV18 L1 VLP enzyme-linked immunoabsorbent assay. Most unvaccinated patients did not have detectable antibody levels, except for a few women above age 25. Both FA and other IBMFS patients developed antibody levels following vaccination that were similar to those previously described in healthy women, and those levels appeared to be sustained out to 5 years after immunization. Thus, antibody responses to the HPV L1 VLP vaccine in patients with FA and other IBMFS appeared to be similar to the responses reported in the general population, implying potential efficacy against future infections with the HPV types contained in the vaccine.

KW - Dyskeratosis congenita

KW - Fanconi anemia

KW - Human papillomavirus

KW - Inherited bone marrow failure syndromes

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84893946909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893946909&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2013.11.048

DO - 10.1016/j.vaccine.2013.11.048

M3 - Article

C2 - 24295807

AN - SCOPUS:84893946909

VL - 32

SP - 1169

EP - 1173

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 10

ER -